A new study on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) entitled “Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis” was published in Respiratory Research by Keishi Oda, part of Dr. Hiroshi Mukae’s group from the Department of Respiratory Medicine at University of Occupational and…
New stem cell research is offering insights into how scientists may someday be able to mitigate lung injury caused by diseases such as IPF. A recent study entitled “The secretome of induced pluripotent stem cells reduces lung fibrosis in part by hepatocyte growth factor” and published…
The Scleroderma Research Foundation will host a free, live webinar on the relationship between pulmonary fibrosis (PF) and scleroderma on Thursday, November 13, at 10:00 a.m. PST. The Director of Biological Research for the Interstitial Lung Disease Program at University of California San Francisco (UCSF), Paul Wolters, will be the main lecturer…
The chief executive officer and president of Pacific Therapeutics, a clinical stage specialty pharmaceutical company dedicated to the development of treatments for fibrosis and erectile dysfunction, commented on the recent interest of big pharmaceutical companies in acquiring therapies for the treatment of fibrosis. Doug Unwin said that…
The National Institutes of Health (NIH) recently granted a $15.6 million award to The University of North Carolina, Chapel Hill (UNC-CH) and The University of Colorado, Denver (UCD), to support five years of research on mucolytic agents. The agents were discovered by the developmental stage biopharmaceutical company Parion Sciences,…
Two subsidiaries of Omnicare Specialty Care Group (SCG) recently announced they have been chosen to provide services to idiopathic pulmonary fibrosis (IPF) patients taking OFEV® (nintedanib), a recently-approved tyrosine kinase inhibitor developed by Boehringer Ingelheim. RxCrossroads and Advanced Care Scripts (ACS) have been selected to carry out reimbursement…
In a study entitled “Development of microscopic polyangiitis-related pulmonary fibrosis in a patient with autoimmune pulmonary alveolar proteinosis” published in BMC Pulmonary Medicine the authors report the first evidence of a relationship between ANCA-associated systemic vasculitis and aPAP-related pulmonary fibrosis. Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare…
The companies Bristol-Myers Squibb and Galecto Biotech AB have signed an agreement giving Bristol the exclusive option to acquire Galecto, as well as the global rights for its lead products, an investigational inhaled inhibitor of galectin-3 for the treatment of idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic…
Promedior, Inc. recently announced in a press release that they have received FDA fast track designation for their compound – PRM-151 – as a promising, new therapeutic for patients with myelofibrosis. The new designation supports continuing evidence that PRM-151 may be a viable therapy for treating a range of diseases…
A novel study on the impact of supplemental oxygen prescription in pulmonary fibrosis entitled “Protocol for a mixed-methods study of supplemental oxygen in pulmonary fibrosis” was published in the journal BMC Pulmonary Medicine by Amanda Belkin, part of Dr. Jeffrey J Swigris’group from Autoimmune Lung Center and Interstitial Lung…
Get regular updates to your inbox.
